AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
With digitally available health records, individuals can avail paper-less health services under Ayushman Bharat Digital Mission (ABDM)
The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products, including a number of generic products focused on women’s health.
Receives regulatory approval for its molecule ‘Selumetinib’ in India
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
Twelve hospitals across India will be part of the network which will support the trial in India
First approval for Daiichi Sankyo and AstraZeneca’s ENHERTU in China
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Subscribe To Our Newsletter & Stay Updated
